Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

ARID1A promotes genomic stability through protecting telomere cohesion.

Zhao B, Lin J, Rong L, Wu S, Deng Z, Fatkhutdinov N, Zundell J, Fukumoto T, Liu Q, Kossenkov A, Jean S, Cadungog MG, Borowsky ME, Drapkin R, Lieberman PM, Abate-Shen CT, Zhang R.

Nat Commun. 2019 Sep 6;10(1):4067. doi: 10.1038/s41467-019-12037-4.

2.

HDAC6 Inhibition Synergizes with Anti-PD-L1 Therapy in ARID1A-Inactivated Ovarian Cancer.

Fukumoto T, Fatkhutdinov N, Zundell JA, Tcyganov EN, Nacarelli T, Karakashev S, Wu S, Liu Q, Gabrilovich DI, Zhang R.

Cancer Res. 2019 Nov 1;79(21):5482-5489. doi: 10.1158/0008-5472.CAN-19-1302. Epub 2019 Jul 16.

PMID:
31311810
3.

ARID1A spatially partitions interphase chromosomes.

Wu S, Fatkhutdinov N, Rosin L, Luppino JM, Iwasaki O, Tanizawa H, Tang HY, Kossenkov AV, Gardini A, Noma KI, Speicher DW, Joyce EF, Zhang R.

Sci Adv. 2019 May 22;5(5):eaaw5294. doi: 10.1126/sciadv.aaw5294. eCollection 2019 May.

4.

N6-Methylation of Adenosine of FZD10 mRNA Contributes to PARP Inhibitor Resistance.

Fukumoto T, Zhu H, Nacarelli T, Karakashev S, Fatkhutdinov N, Wu S, Liu P, Kossenkov AV, Showe LC, Jean S, Zhang L, Zhang R.

Cancer Res. 2019 Jun 1;79(11):2812-2820. doi: 10.1158/0008-5472.CAN-18-3592. Epub 2019 Apr 9.

PMID:
30967398
5.

NAD+ metabolism governs the proinflammatory senescence-associated secretome.

Nacarelli T, Lau L, Fukumoto T, Zundell J, Fatkhutdinov N, Wu S, Aird KM, Iwasaki O, Kossenkov AV, Schultz D, Noma KI, Baur JA, Schug Z, Tang HY, Speicher DW, David G, Zhang R.

Nat Cell Biol. 2019 Mar;21(3):397-407. doi: 10.1038/s41556-019-0287-4. Epub 2019 Feb 18.

6.

SWI/SNF catalytic subunits' switch drives resistance to EZH2 inhibitors in ARID1A-mutated cells.

Wu S, Fatkhutdinov N, Fukumoto T, Bitler BG, Park PH, Kossenkov AV, Trizzino M, Tang HY, Zhang L, Gardini A, Speicher DW, Zhang R.

Nat Commun. 2018 Oct 8;9(1):4116. doi: 10.1038/s41467-018-06656-6.

7.

Repurposing Pan-HDAC Inhibitors for ARID1A-Mutated Ovarian Cancer.

Fukumoto T, Park PH, Wu S, Fatkhutdinov N, Karakashev S, Nacarelli T, Kossenkov AV, Speicher DW, Jean S, Zhang L, Wang TL, Shih IM, Conejo-Garcia JR, Bitler BG, Zhang R.

Cell Rep. 2018 Mar 27;22(13):3393-3400. doi: 10.1016/j.celrep.2018.03.019.

8.

Harnessing mutual exclusivity between TP53 and ARID1 A mutations.

Wu S, Fatkhutdinov N, Zhang R.

Cell Cycle. 2017;16(24):2313-2314. doi: 10.1080/15384101.2017.1377503. No abstract available.

9.

BET Bromodomain Inhibition Synergizes with PARP Inhibitor in Epithelial Ovarian Cancer.

Karakashev S, Zhu H, Yokoyama Y, Zhao B, Fatkhutdinov N, Kossenkov AV, Wilson AJ, Simpkins F, Speicher D, Khabele D, Bitler BG, Zhang R.

Cell Rep. 2017 Dec 19;21(12):3398-3405. doi: 10.1016/j.celrep.2017.11.095.

10.

HMGB2 orchestrates the chromatin landscape of senescence-associated secretory phenotype gene loci.

Aird KM, Iwasaki O, Kossenkov AV, Tanizawa H, Fatkhutdinov N, Bitler BG, Le L, Alicea G, Yang TL, Johnson FB, Noma KI, Zhang R.

J Cell Biol. 2016 Nov 7;215(3):325-334. Epub 2016 Oct 31.

11.

Targeting RRM2 and Mutant BRAF Is a Novel Combinatorial Strategy for Melanoma.

Fatkhutdinov N, Sproesser K, Krepler C, Liu Q, Brafford PA, Herlyn M, Aird KM, Zhang R.

Mol Cancer Res. 2016 Sep;14(9):767-75. doi: 10.1158/1541-7786.MCR-16-0099. Epub 2016 Jun 13.

12.

Potential therapeutic targets in ARID1A-mutated cancers.

Bitler BG, Fatkhutdinov N, Zhang R.

Expert Opin Ther Targets. 2015;19(11):1419-22. doi: 10.1517/14728222.2015.1062879. Epub 2015 Jun 30. Review.

Supplemental Content

Loading ...
Support Center